000863758 001__ 863758
000863758 005__ 20220930130214.0
000863758 0247_ $$2doi$$a10.1007/s00401-019-02037-5
000863758 0247_ $$2ISSN$$a0001-6322
000863758 0247_ $$2ISSN$$a1432-0533
000863758 0247_ $$2Handle$$a2128/23869
000863758 0247_ $$2altmetric$$aaltmetric:62634082
000863758 0247_ $$2pmid$$apmid:31230104
000863758 0247_ $$2WOS$$aWOS:000488931000003
000863758 037__ $$aFZJ-2019-03756
000863758 082__ $$a610
000863758 1001_ $$0P:(DE-HGF)0$$aLohmann, Stephanie$$b0
000863758 245__ $$aOral and intravenous transmission of α-synuclein fibrils to mice
000863758 260__ $$aHeidelberg$$bSpringer$$c2019
000863758 3367_ $$2DRIVER$$aarticle
000863758 3367_ $$2DataCite$$aOutput Types/Journal article
000863758 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1579098898_7499
000863758 3367_ $$2BibTeX$$aARTICLE
000863758 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000863758 3367_ $$00$$2EndNote$$aJournal Article
000863758 520__ $$aParkinson’s disease and related disorders are neuropathologically characterized by cellular deposits of misfolded and aggregated α-synuclein in the CNS. Disease-associated α-synuclein adopts a conformation that causes it to form oligomers and fibrils, which have reduced solubility, become hyperphosphorylated, and contribute to the spatiotemporal spreading of pathology in the CNS. The infectious properties of disease-associated α-synuclein, e.g., by which peripheral route and with which efficiency it can be transmitted, are not fully understood. Here, we investigated the potential of α-synuclein fibrils to induce neurological disease in TgM83+/− mice expressing the A53T mutant of human α-synuclein after oral or intravenous challenge and compared it to intraperitoneal and intracerebral challenge. Oral challenge with 50 µg of α-synuclein fibrils caused neurological disease in two out of eight mice in 220 days and 350 days, and challenge with 500 µg in four out of eight mice in 384 ± 131 days, respectively. Intravenous challenge with 50 µg of α-synuclein fibrils led to disease in 208 ± 20 days in 10 out of 10 mice and was in duration comparable to intraperitoneal challenge with 50 µg of α-synuclein fibrils, which caused disease in 10 out of 10 mice in 202 ± 35 days. Ten out of 10 mice that were each intracerebrally challenged with 10 µg or 50 µg of α-synuclein fibrils developed disease in 156 ± 20 days and 133 ± 4 days, respectively. The CNS of diseased mice displayed aggregates of sarkosyl-insoluble and phosphorylated α-synuclein, which colocalized with ubiquitin and p62 and were accompanied by gliosis indicative of neuroinflammation. In contrast, none of the control mice that were challenged with bovine serum albumin via the same routes developed any neurological disease or neuropathology. These findings are important, because they show that α-synuclein fibrils can neuroinvade the CNS after a single oral or intravenous challenge and cause neuropathology and disease.
000863758 536__ $$0G:(DE-HGF)POF3-553$$a553 - Physical Basis of Diseases (POF3-553)$$cPOF3-553$$fPOF III$$x0
000863758 588__ $$aDataset connected to CrossRef
000863758 7001_ $$0P:(DE-HGF)0$$aBernis, Maria E.$$b1
000863758 7001_ $$0P:(DE-HGF)0$$aTachu, Babila J.$$b2
000863758 7001_ $$0P:(DE-Juel1)177951$$aZiemski, Alexandra$$b3
000863758 7001_ $$0P:(DE-HGF)0$$aGrigoletto, Jessica$$b4
000863758 7001_ $$0P:(DE-HGF)0$$aTamgüney, Gültekin$$b5$$eCorresponding author
000863758 773__ $$0PERI:(DE-600)1458410-4$$a10.1007/s00401-019-02037-5$$gVol. 138, no. 4, p. 515 - 533$$n4$$p515 - 533$$tActa neuropathologica$$v138$$x1432-0533$$y2019
000863758 8564_ $$uhttps://juser.fz-juelich.de/record/863758/files/20190710114816790.pdf
000863758 8564_ $$uhttps://juser.fz-juelich.de/record/863758/files/20190710114816790.pdf?subformat=pdfa$$xpdfa
000863758 8564_ $$uhttps://juser.fz-juelich.de/record/863758/files/Lohmann2019_Article_OralAndIntravenousTransmission-1.pdf$$yOpenAccess
000863758 8564_ $$uhttps://juser.fz-juelich.de/record/863758/files/Lohmann2019_Article_OralAndIntravenousTransmission-1.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000863758 8767_ $$82936137503$$92019-06-26$$d2019-07-10$$eHybrid-OA$$jZahlung erfolgt
000863758 909CO $$ooai:juser.fz-juelich.de:863758$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$pdnbdelivery
000863758 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177951$$aForschungszentrum Jülich$$b3$$kFZJ
000863758 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-HGF)0$$aForschungszentrum Jülich$$b5$$kFZJ
000863758 9131_ $$0G:(DE-HGF)POF3-553$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vPhysical Basis of Diseases$$x0
000863758 9141_ $$y2019
000863758 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000863758 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000863758 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000863758 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000863758 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bACTA NEUROPATHOL : 2017
000863758 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL : 2017
000863758 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000863758 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000863758 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000863758 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000863758 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000863758 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000863758 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000863758 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000863758 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000863758 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000863758 9201_ $$0I:(DE-Juel1)ICS-6-20110106$$kICS-6$$lStrukturbiochemie$$x0
000863758 9801_ $$aAPC
000863758 9801_ $$aFullTexts
000863758 980__ $$ajournal
000863758 980__ $$aVDB
000863758 980__ $$aUNRESTRICTED
000863758 980__ $$aI:(DE-Juel1)ICS-6-20110106
000863758 980__ $$aAPC
000863758 981__ $$aI:(DE-Juel1)IBI-7-20200312